Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.101453 | 1 | 1 | |
Plasmodium vivax | hexokinase, putative | 0.101453 | 1 | 0.5 |
Toxoplasma gondii | hexokinase | 0.101453 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase type II | 0.101453 | 1 | 1 |
Loa Loa (eye worm) | hexokinase | 0.0623472 | 0.272488 | 0.272488 |
Trypanosoma brucei | hexokinase | 0.101453 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.101453 | 1 | 0.5 |
Onchocerca volvulus | 0.101453 | 1 | 1 | |
Leishmania major | hexokinase, putative | 0.101453 | 1 | 0.5 |
Trypanosoma brucei | hexokinase | 0.101453 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.101453 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.101453 | 1 | 0.5 |
Leishmania major | hexokinase, putative | 0.101453 | 1 | 0.5 |
Brugia malayi | hexokinase | 0.101453 | 1 | 1 |
Echinococcus multilocularis | hexokinase | 0.101453 | 1 | 0.5 |
Trypanosoma brucei | hexokinase, putative | 0.101453 | 1 | 0.5 |
Trypanosoma cruzi | hexokinase, putative | 0.101453 | 1 | 0.5 |
Trypanosoma cruzi | hexokinase, putative | 0.101453 | 1 | 0.5 |
Schistosoma mansoni | hexokinase | 0.101453 | 1 | 0.5 |
Entamoeba histolytica | hexokinase 2 | 0.101453 | 1 | 0.5 |
Brugia malayi | Hexokinase family protein | 0.101453 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0696108 | 0.407618 | 0.407618 |
Plasmodium falciparum | hexokinase | 0.101453 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase | 0.101453 | 1 | 1 |
Entamoeba histolytica | hexokinase 1 | 0.101453 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase | 0.101453 | 1 | 1 |
Treponema pallidum | hexokinase (hxk) | 0.101453 | 1 | 0.5 |
Echinococcus granulosus | hexokinase type 2 | 0.101453 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.101453 | 1 | 0.5 |
Onchocerca volvulus | 0.101453 | 1 | 1 | |
Echinococcus granulosus | hexokinase | 0.101453 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase type 2 | 0.101453 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence. | ChEMBL. | 22096101 | |
CC50 (functional) | > 100 uM | Huh7 cytotoxicity for Pf inhibitors | Novartis-GNF Malaria Box. | No reference |
CC50 | > 100 uM | NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) | ChEMBL. | 18579783 |
EC50 (functional) | = 0.633 uM | PF proliferation inhibition 3D7 | Novartis-GNF Malaria Box. | No reference |
EC50 (functional) | = 0.633 uM | NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay | ChEMBL. | 18579783 |
EC50 (functional) | = 2.261 uM | W2 Pf proliferation inhibition | Novartis-GNF Malaria Box. | No reference |
EC50 (functional) | = 2.261 uM | NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay | ChEMBL. | 18579783 |
IFI promiscuity index | = 0 | IFI promiscuity index | Novartis-GNF Malaria Box. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | 18579783 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.